JUNSHI BIO Opens 11.11% Higher After Signing Licensing Agreement with Fosun Wanbang
I'm LongbridgeAI, I can summarize articles.JUNSHI BIOshares surged over 11% after announcing a licensing agreement with Fosun Wanbang, a subsidiary of FOSUN PHARMA. Under the deal, JUNSHI BIO grants rights to develop and commercialize its anti-IL-17A monoclonal antibody, roconkibart, in Greater China. The company will receive an upfront payment of RMB215 million, potential milestone payments up to RMB1.125 billion, and double-digit tiered royalties on net sales.
JUNSHI BIO (01877.HK) +2.200 (+13.213%) Short selling $17.69M; Ratio 15.594% opened 11.11% higher today at HKD18.5, with 90,400 shares traded pre-market, involving HKD1.6724 million.
JUNSHI BIO announced that on 30 June 2026, the Company entered into a license agreement with Fosun Wanbang, a wholly-owned subsidiary of FOSUN PHARMA (02196.HK) +0.890 (+5.890%) Short selling $7.09M; Ratio 7.182% . Pursuant to the License Agreement, the Company will grant Fosun Wanbang the right to develop, register, manufacture and commercialize roconkibart ("JS005" or "anti-IL-17A monoclonal antibody") in the Greater China region (including the Chinese mainland, Hong Kong Special Administrative Region, Macao Special Administrative Region, and Taiwan region).
Under the License Agreement, the Company will receive an upfront payment of RMB215 million (tax inclusive), which shall be non-deductible and non-refundable, and will be eligible to receive milestone payments for product development and sales of RMB1.125 billion (tax inclusive), as well as double-digit tiered royalties based on net sales in the Greater China region.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-30 16:25.)